Skip to main content

Mylan gets FDA approval for AstraZeneca drug generic


PITTSBURGH The Food and Drug Administration has approved Mylan’s generic version of a drug for treating prostate cancer.

Mylan announced Tuesday the approval of bicalutamide tablets in the 50-mg strength. The tablets are a generic version of AstraZeneca’s Casodex, which had U.S. sales of $322 million for the 12 months ended March 31 in the same strength, according to IMS Health data, and global sales of $1.26 billion, according to AstraZeneca financial data.

Teva announced Monday the launch of its own version of the drug.

This ad will auto-close in 10 seconds